Tag: Asterias Biotherapeutics

Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials FREMONT, Calif., July 10,...

Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on...

Early clinical trial results announced offer new hope in regenerative medicine A new therapy to treat spinal cord injuries in people who have lost all...

An experimental stem cell therapy developed by Asterias Biotherapeutics restored some movement to patients paralyzed by recent spinal cord injuries, according to interim data...

Initial Results Offer Hope for Patients to Reclaim Independence After Suffering Severe Spinal Injury LOS ANGELES, Sept. 7, 2016 /PRNewswire/ -- Keck Medical Center...

Oakland, CA – A clinical trial using stem cells to treat people with recent spinal cord injuries has cleared two key safety hurdles, and...

StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries. StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries.

Summary Four biotech companies are pursuing the treatment of spinal cord injury with the use of stem cell transplantation. Each company demonstrated efficacy in pre-clinical studies. The...

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one...

An experimental treatment using controversial embryonic stem cells to fix severe spinal cord injuries has new life under a new company. Asterias Biotherapeutics Inc. of...